US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

266.00

-13.0200-4.67%

Post-market: 266.000.00000.00%16:10 EDT

Volume:288.28K

Turnover:77.00M

Market Cap:498.61M

PE:- -

High:274.71

Open:269.37

Low:260.01

Close:279.02

52wk High:341.93

52wk Low:74.95

Shares:1.87M

Float Shares:1.87M

Volume Ratio:0.94

T/O Rate:15.38%

Dividend:1.00

Dividend Rate:0.38%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Cycurion Secures New Healthcare and Public Health Contracts

Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform

ICU Girişim Sermayesi Details Diversified Venture Portfolio in Healthcare and Technology

Dennis Ding Reiterates Buy on Tarsus, Highlighting Robust Xdemvy Trends, Conservative 2026 Guidance, and Attractive Valuation Backed by Late-Stage Pipeline

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)

Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged

Health Care Roundup: Market Talk

HCA Healthcare Delivers Consistent Message Around H2 Cadence Expectations, RBC Says

MT Newswires Live

RedHill Biopharma Pushes for Growth Securing Rights to Ferring’s $37M Gastrointestinal Drugs Portfolio

Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and MiMedx Group (MDXG)

Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

Surrozen submits investigational new drug application for SZN-8141

Quoin Pharmaceuticals granted Rare Pediatric Disease Designation for QRX003

Sector Update: Healthcare

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

Concord Healthcare Controlling Shareholder Revises H-Share Pledge for Smaller Loan

Definium Therapeutics Gains FDA Breakthrough for Depression Drug

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Intellia Therapeutics announces FDA acceptance of lonvo-z BLA

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/LABU/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":266,"timestamp":1789070400000,"preClose":279.02,"halted":0,"volume":288284,"hourTrading":{"tag":"盘后","latestPrice":266,"preClose":266,"latestTime":"16:10 EDT","volume":37,"amount":9810.53076,"timestamp":1789071008226,"change":0,"changeRate":0,"amplitude":0.007519},"delay":0,"changeRate":-0.046663321625689855,"floatShares":1874486,"shares":1874486,"eps":0,"marketStatus":"Post-Mkt","change":-13.02,"latestTime":"09-10 16:12:16 EDT","open":269.37,"high":274.705,"low":260.01,"amount":76995380.8028,"amplitude":0.052666,"askPrice":266.4,"askSize":200,"bidPrice":264,"bidSize":200,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":279.02,"sharesOutstanding":3074486,"nav":292.443,"aum":548181239.8,"dividendRate":0.003776,"bidAskSpread":0.003029,"preHourTrading":{"tag":"盘前","latestPrice":268.99,"preClose":279.02,"latestTime":"09:29 EDT","volume":1828,"amount":503835.0052,"timestamp":1789046962415,"change":-10.03,"changeRate":-0.035947,"amplitude":0.054249},"postHourTrading":{"tag":"盘后","latestPrice":266,"preClose":266,"latestTime":"16:10 EDT","volume":37,"amount":9810.53076,"timestamp":1789071008226,"change":0,"changeRate":0,"amplitude":0.007519},"volumeRatio":0.938308,"impliedVol":0.9034,"impliedVolPercentile":0.4821},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1874486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.938308,"shares":1874486,"dividePrice":1.0045,"high":274.705,"amplitude":0.052666,"preClose":279.02,"low":260.01,"week52Low":74.95,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":266,"eps":0,"divideRate":0.003776,"volume":288284,"delay":0,"ttmEps":0,"open":269.37,"prevYearClose":159.39,"prevWeekClose":303.55,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":311.81,"twentyDayClose":286.75,"sixtyDayClose":188.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666372275","title":"Cycurion Secures New Healthcare and Public Health Contracts","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372275","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372275?lang=en_us&edition=fundamental","pubTime":"2026-09-09 03:47","pubTimestamp":1788896876,"startTime":"0","endTime":"0","summary":"Cycurion ( ($CYCU) ) has shared an update. On September 3, 2026, Cycurion announced new engagements totaling about $800,000 in annual contract spen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cycurion-secures-new-healthcare-and-public-health-contracts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cycurion-secures-new-healthcare-and-public-health-contracts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LABU","BK4137","BK4585","CYCU","HCSG","XBI","LU0029874061.USD","XLV","BK4581","BK4123","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372293","title":"Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372293","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372293?lang=en_us&edition=fundamental","pubTime":"2026-09-09 03:45","pubTimestamp":1788896725,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush maintained a Buy ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-sarepta-keeping-35-price-target-amid-confidence-in-dm1-franchise-and-integrin-delivery-platform-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-sarepta-keeping-35-price-target-amid-confidence-in-dm1-franchise-and-integrin-delivery-platform-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LABU","XLV","BK4581","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666273374","title":"ICU Girişim Sermayesi Details Diversified Venture Portfolio in Healthcare and Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2666273374","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666273374?lang=en_us&edition=fundamental","pubTime":"2026-09-09 02:12","pubTimestamp":1788891143,"startTime":"0","endTime":"0","summary":"ICU Girisim Sermayesi Yatirim Ortakligi A.S. ( ($TR:ICUGS) ) has provided an announcement. ICU Girişim Sermayesi Yatırım Ortaklığı A.Ş. has detaile...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/icu-girisim-sermayesi-details-diversified-venture-portfolio-in-healthcare-and-technology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/icu-girisim-sermayesi-details-diversified-venture-portfolio-in-healthcare-and-technology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0029874061.USD","XLV","LABU","HCSG","BK4585","BK4588","LU0128526141.USD","BK4137","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374136","title":"Dennis Ding Reiterates Buy on Tarsus, Highlighting Robust Xdemvy Trends, Conservative 2026 Guidance, and Attractive Valuation Backed by Late-Stage Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374136?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:55","pubTimestamp":1788890117,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Dennis Ding from Jefferies reiterated ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/dennis-ding-reiterates-buy-on-tarsus-highlighting-robust-xdemvy-trends-conservative-2026-guidance-and-attractive-valuation-backed-by-late-stage-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/dennis-ding-reiterates-buy-on-tarsus-highlighting-robust-xdemvy-trends-conservative-2026-guidance-and-attractive-valuation-backed-by-late-stage-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4007","BK4588","LABU","TARS","XLV","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374637","title":"Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374637?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:20","pubTimestamp":1788888012,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and BioCryst (BCRX) with b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-biocryst-bcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-biocryst-bcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XLV","LU0128526141.USD","HCSG","BK4547","BK4588","LU0029874061.USD","SYRE","BK4585","LABU","XBI","LFSC","BCRX","BK4137","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666275371","title":"Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666275371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666275371?lang=en_us&edition=fundamental","pubTime":"2026-09-09 00:40","pubTimestamp":1788885608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on enGene Holdings (ENGN) and Structure Therapeutics, I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-engene-holdings-engn-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-engene-holdings-engn-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HCSG","BK4599","SAPH","XLV","DIVL","LU0128526141.USD","AADR","XBI","ENGN","CVY","LU0029874061.USD","BK4588","BK4137","ARMH","BK4581","BK4585","LABU","DINT","GPCR","BK4139","APIE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666371411","title":"Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2666371411","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666371411?lang=en_us&edition=fundamental","pubTime":"2026-09-09 00:35","pubTimestamp":1788885338,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from H.C. Wainwright rei...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sell-rating-reaffirmed-on-weakening-core-franchise-and-elevated-clinical-risk-5-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sell-rating-reaffirmed-on-weakening-core-franchise-and-elevated-clinical-risk-5-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LABU","XLV","BK4581","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666371944","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2666371944","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666371944?lang=en_us&edition=fundamental","pubTime":"2026-09-09 00:20","pubTimestamp":1788884400,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0417 ET - Novartis's latest clinical-trial failure suggests the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XBI","XLV","LABU","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665737976","title":"HCA Healthcare Delivers Consistent Message Around H2 Cadence Expectations, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2665737976","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665737976?lang=en_us&edition=fundamental","pubTime":"2026-09-08 23:43","pubTimestamp":1788882197,"startTime":"0","endTime":"0","summary":"HCA Healthcare's (HCA) management delivered a consistent message around second-half cadence expectations, with a more difficult comparison ahead for Q3 and a relatively more favorable comparison for Q","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1084165304.USD","LU1150488218.USD","LU0068578508.USD","SG9999014021.USD","LU1119994496.HKD","LU1201861249.SGD","SG9999014005.SGD","LU0868494617.USD","BK4185","IE00B3S45H60.SGD","IHF","HCA","LABU","LU0878866978.SGD","LU1267930490.SGD","IE00B775SV38.USD","LU1267930573.SGD","LU2355687059.USD","SG9999014013.SGD","BK4504","BK4585","XLV","LU0211327993.USD","SG9999014039.USD","LU0310799852.SGD","LU0985489474.SGD","LU0187121727.USD","LU0708994859.HKD","LU1150488135.SGD","BK4588","LU1261432733.SGD","LU0648001328.SGD","LU0114720955.EUR","LU0882574055.USD","LU0211328371.USD","LU1489326972.SGD","LU0310800379.SGD","LU0130102774.USD","LU0433182093.SGD","LU0203345920.USD","BK4581","LU0029864427.USD","LU0203347892.USD","LU0128525929.USD","LU2244417387.USD","XBI","LU0980610538.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665793803","title":"RedHill Biopharma Pushes for Growth Securing Rights to Ferring’s $37M Gastrointestinal Drugs Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2665793803","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665793803?lang=en_us&edition=fundamental","pubTime":"2026-09-08 22:49","pubTimestamp":1788878982,"startTime":"0","endTime":"0","summary":"RedHill Biopharma ($RHDL) has said the acquisition from Ferring of commercialization rights to two established gastrointestinal (GI) FDA-approved d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/redhill-biopharma-pushes-for-growth-securing-rights-to-ferrings-37m-gastrointestinal-drugs-portfolio?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/redhill-biopharma-pushes-for-growth-securing-rights-to-ferrings-37m-gastrointestinal-drugs-portfolio?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375964","title":"Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and MiMedx Group (MDXG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375964","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375964?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:20","pubTimestamp":1788873611,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Establishment Labs Holdings (ESTA) and MiMedx Group ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-establishment-labs-holdings-esta-and-mimedx-group-mdxg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-establishment-labs-holdings-esta-and-mimedx-group-mdxg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","LU2324357040.USD","ESTA","BK4588","MDXG","XBI","XLV","LABU","BK4139","LU0128526141.USD","BK4198","BK4137","BK4585","BK4581","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665013373","title":"Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums","url":"https://stock-news.laohu8.com/highlight/detail?id=2665013373","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665013373?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:15","pubTimestamp":1788873300,"startTime":"0","endTime":"0","summary":"Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September CEO Abizer Gaslightwala to deliver keynote a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357752/0/en/akari-therapeutics-selected-to-showcase-novel-ph1-adc-payload-platform-at-leading-global-oncology-adc-and-healthcare-forums.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","LENZ","BK4581","HCSG","XBI","XLV","BK4139","LABU","BK4588","LU0128526141.USD","BK4007","LU0029874061.USD","BK4585","BK4539","IEIH","BK4137","CST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375834","title":"Surrozen submits investigational new drug application for SZN-8141","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375834?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:10","pubTimestamp":1788873057,"startTime":"0","endTime":"0","summary":"Surrozen (SRZN) announced the submission of an investigational new drug application to the FDA seeking to evaluate SZN-8141, a bifunctional Wnt ago...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/surrozen-submits-investigational-new-drug-application-for-szn-8141-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/surrozen-submits-investigational-new-drug-application-for-szn-8141-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","BK4585","LABU","SRZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665537583","title":"Quoin Pharmaceuticals granted Rare Pediatric Disease Designation for QRX003","url":"https://stock-news.laohu8.com/highlight/detail?id=2665537583","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665537583?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:05","pubTimestamp":1788872727,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that the FDA has granted Rare Pediatric Disease Designation for the company’s lead asset, QRX003, for the tr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-granted-rare-pediatric-disease-designation-for-qrx003-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-granted-rare-pediatric-disease-designation-for-qrx003-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LABU","BK4585","BK4588","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373903","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373903","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665373903?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:02","pubTimestamp":1788872523,"startTime":"0","endTime":"0","summary":"Financial stocks were flat to lower pre-bell Tuesday, with the iShares Biotechnology ETF  inactive and the State Street Health Care Select Sector SPDR ETF  declining by 1.3%.Novartis  stock was down more than 12% after the company said its late-stage study evaluating delpacibart etedesiran in patients with myotonic dystrophy type 1 has failed to meet its primary endpoint of video hand opening time.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4578","LABU","IE00B2B36J28.USD","LU0320765489.SGD","XLV","PPH","LU0029874061.USD","LU0208291251.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0070302665.USD","LU0211331839.USD","LU0128526141.USD","BK4532","IBB","BK4581","HCSG","BK4137","MEDX","IE0002141913.USD","IE0009355771.USD","NVS","BK4585","BK4007","IE00BFTCPJ56.SGD","XBI","BK4588","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373511","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665373511?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:51","pubTimestamp":1788871865,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN), Guardant Health (GH) and Neurocrine (N...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0823416689.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU0289739699.SGD","GNMX","AMGN","LU1057294990.SGD","LU2242646821.SGD","BK4137","PBE","LU0889565916.HKD","LU0109394709.USD","XLV","IE00BJT1NW94.SGD","BIB","BBH","NBIX","BK4588","LU0154245756.USD","XBI","BK4599","LU0058720904.USD","HELX","BK4534","LU2242652126.USD","GDOC","LU2468319806.SGD","LU0029874061.USD","IBB","PJP","PTH","BK4585","TBXU","BK4535","IE0002141913.USD","GH","HCSG","BK4139","LABU","FFOX","LFSC","IBBQ","BK4533","LU1571399168.USD","LU2065170008.USD","LU0154245673.USD","GNOM","EKG","IE0009355771.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378258","title":"Concord Healthcare Controlling Shareholder Revises H-Share Pledge for Smaller Loan","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378258","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378258?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:37","pubTimestamp":1788871052,"startTime":"0","endTime":"0","summary":"Concord Healthcare Group Co., Ltd. Class H ( ($HK:2453) ) just unveiled an announcement. Concord Healthcare Group Co., Ltd. has disclosed that its ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/concord-healthcare-controlling-shareholder-revises-h-share-pledge-for-smaller-loan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/concord-healthcare-controlling-shareholder-revises-h-share-pledge-for-smaller-loan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4588","BK4137","LU0029874061.USD","LABU","BK4581","HCSG","CNDA","XLV","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665937815","title":"Definium Therapeutics Gains FDA Breakthrough for Depression Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2665937815","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665937815?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:35","pubTimestamp":1788870934,"startTime":"0","endTime":"0","summary":"Definium Therapeutics ( ($DFTX) ) just unveiled an announcement. On September 8, 2026, Definium Therapeutics announced that the U.S. Food and Drug ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-gains-fda-breakthrough-for-depression-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-gains-fda-breakthrough-for-depression-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007","LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378198","title":"CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378198","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378198?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:30","pubTimestamp":1788870600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, Sept.  08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th A","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357662/0/en/crispr-therapeutics-to-present-at-the-morgan-stanley-24th-annual-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LU1861559042.SGD","BK4137","ARKG","SYNB","BK4139","BK4588","XLV","BK4556","BK4581","LU0128526141.USD","BK4585","CRSP","LU0029874061.USD","HCSG","LU1861558580.USD","LABU","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320747","title":"Intellia Therapeutics announces FDA acceptance of lonvo-z BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320747","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320747?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:11","pubTimestamp":1788869463,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) announced the FDA has accepted the biologics license application for lonvo-z and granted the BLA Priority Review with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-announces-fda-acceptance-of-lonvo-z-bla-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-announces-fda-acceptance-of-lonvo-z-bla-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","BK4139","BK4588","NTLA","BK4556","BK4585","BK4535","LU1861558580.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":5,"totalSize":413,"code":"91000000","status":"200"}]}}